Merck gains rights to NewLink Genetics investigational Ebola vaccine

24 November 2014

US pharma giant Merck & Co (NYSE: MRK) has entered into an exclusive worldwide license agreement to research, develop, manufacture, and distribute US biotech firm NewLink Genetics' (Nasdaq: NLNK) investigational rVSV-EBOV (Ebola) vaccine candidate.

Although financial terms of the collaboration were not revealed, New Link’s shares initially gained 2.3% to $36.15, before flattening out. NewLink shares, meanwhile, have gained 60.5% in the year to date.

Just last month NewLink signed a deal with Genentech, a Roche (ROG: SIX) subsidiary, potentially worth more than $1.15 billion for the development of NLG919, NewLink's IDO pathway inhibitor (The Pharma Letter October 20). The parties also entered into a research collaboration for the discovery of next generation IDO/TDO compounds.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology